Gastroparesis Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Gastroparesis Market Overview

Gastroparesis is an increasingly recognized gastrointestinal condition that affects stomach motility and disrupts normal digestion. Its symptoms, including nausea, vomiting, bloating, and early satiety, can significantly affect nutritional intake, daily activities, and quality of life, creating a need for effective symptom management and long-term care. The market is poised to grow at a CAGR of 4.50% during the forecast period of 2026-2035, driven by growing disease awareness, improvements in diagnostic approaches, and ongoing research into pharmacological treatments. Market development focuses on prokinetic agents, antiemetics, and emerging therapies designed to improve gastric emptying and control symptoms. Unmet treatment needs, limitations of existing medications, and continued clinical research are shaping therapeutic innovation and future market opportunities.

Gastroparesis Market Growth Analysis and Key Influencers

Gastroparesis Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Gastroparesis Market Growth Drivers

Expanding Access to Advanced Therapies Supports Market Expansion

The growing availability of advanced treatment options for persistent gastroparesis symptoms is supporting market development. Patients who do not respond adequately to dietary modifications and medications may require alternative approaches to symptom management. For instance, in August 2026, the University of Arkansas for Medical Sciences (UAMS) announced that it had begun offering Enterra Therapy, a minimally invasive gastric electrical stimulation treatment designed to relieve chronic nausea and vomiting associated with gastroparesis. This development highlights expanding access to specialized care and advanced treatment options, supporting the market's growth.

Gastroparesis Market Restraints

Clinical Trial Challenges May Limit Market Growth

The development of effective gastroparesis treatments faces challenges associated with variable symptom severity, subjective patient reporting, and substantial placebo responses in clinical trials. These factors can complicate the evaluation of treatment efficacy and increase the difficulty of demonstrating consistent clinical benefits. Uncertain trial outcomes may delay regulatory approval, extend development timelines, and increase research costs. Consequently, pharmaceutical companies may face greater development risks, potentially limiting the introduction of new therapies and slowing market expansion.

Gastroparesis Market Opportunities

Development of Novel Drug Candidates Could Strengthen the Market Value

The development of innovative medicines targeting gastroparesis symptoms presents potential for market expansion, particularly given the limited availability of effective long-term treatment options. New therapies may help address persistent symptoms and unmet patient needs. For instance, in June 2024, Renexxion Ireland Limited received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for naronapride, an investigational oral therapy for gastroparesis. Following this regulatory clearance, Renexxion and its European partner, Dr. Falk Pharma GmbH, planned to expand patient recruitment for the ongoing Phase 2b MOVE-IT clinical trial to include sites in the United States. Continued clinical and regulatory progress in novel drug development could broaden future treatment options and support market growth.

Gastroparesis Market Trends

The market is witnessing several trends, including advanced gastric electrical stimulation technologies and the development of novel prokinetic therapies.

Advancements in Drug Development Are Likely to Support Market Landscape

The development of novel medicines targeting gastrointestinal motility and gastroparesis symptoms is an emerging trend. For instance, in October 2026, Dr. Falk Pharma and Renexxion announced alignment with the U.S. Food and Drug Administration and the European Medicines Agency on the Phase 3 development program for naronapride, including trial design and endpoints. This progress reflects continued investment in late-stage drug development and may support future treatment innovation and market growth.

Gastroparesis Market Share

Gastric Electrical Stimulation Devices Are Positioned to Support Market Expansion by Device Type

The market is segmented by device type into gastric electrical stimulation (GES) devices, gastric decompression devices, enteral feeding tubes, jejunal feeding tubes, and others. Gastric electrical stimulation (GES) devices are expected to represent a leading segment, supported by technological improvements and their role in managing chronic nausea and vomiting associated with gastroparesis. For instance, in January 2026, Enterra Medical introduced Enterra ReliaStim, an FDA-approved stimulation lead designed to improve the precision, consistency, and efficiency of GES lead placement. Such advances may strengthen the adoption of GES technologies and support market growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Gastroparesis Market Analysis by Region

The regions included in the report are United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these countries, the United States is expected to remain a leading market, supported by the recognized burden of gastroparesis and access to specialized diagnosis and treatment. Endocrinology Advisor estimates the standardized prevalence of gastroparesis in the United States at approximately 267 cases per 100,000 people, although estimates were lower among patients with confirmed disease. This disease burden supports demand for treatment options and continued market development.

Leading Players in the Gastroparesis Market

Gastroparesis Market Segmentation

Key Questions Answered in the Gastroparesis Market Report

• What was the gastroparesis market value in 2025?
• What is the gastroparesis market forecast outlook for 2026-2035?
• What are the major factors aiding the gastroparesis market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major gastroparesis market trends?
• Which drug class is expected to dominate the market segment?
• Which device type is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Which end user is expected to lead the market segment?
• Who are the key players involved in the gastroparesis market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report employs a mixed-methods research design to assess the gastroparesis market across the eight major markets.

• Primary Research: Expert consultations with gastroenterologists, healthcare professionals, pharmaceutical industry specialists, medical device experts, and healthcare procurement stakeholders to understand treatment patterns, unmet needs, market access, and adoption trends.
• Secondary Research: Analysis of peer-reviewed publications, clinical trial records from ClinicalTrials.gov, regulatory information from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA), alongside company websites, product information, and published clinical research on gastroparesis treatments.
• Validation: Market estimates and forecasts are assessed through cross-verification of available data, comparative analysis, and consistency checks to support reliable market projections.